FULL TEST BANK FOR
PHARMACOTHERAPEUTICS FOR NURSE PRACTITIONER
PRESCRIBERS 3RD EDITION
BY WOO (COVERS ALL CHAPTERS 1-50 WITH ANSWER KEY)
,TABLE OF CONTENTS
Chapter 1: The Role Of The Nurse Practitioner As Prescriber ................................................................................................. 4
Chapter 2: Review Of Basic Principles Of Pharmacology ....................................................................................................... 5
Chapter 3: Rational Drug Selection......................................................................................................................................... 10
Chapter 4: Legal And Professional Issues In Prescribing ....................................................................................................... 13
Chapter 5: Adverse Drug Reactions ........................................................................................................................................ 15
Chapter 6: Factors That Foster Positive Outcomes ................................................................................................................. 18
Chapter 7: Cultural And Ethnic Influences In Pharmacotherapeutics..................................................................................... 21
Chapter 8: Pharmacogenomics ................................................................................................................................................ 23
Chapter 9: Nutritional Supplements And Nutraceuticals ........................................................................................................ 26
Chapter 10: Herbal And Complementary Medicine ............................................................................................................... 31
Chapter 11: Information Technology And Pharmacotherapeutics ......................................................................................... 34
Chapter 12: Pharmacoeconomics............................................................................................................................................. 37
Chapter 13: Over-The-Counter Medications ........................................................................................................................... 40
Chapter 14: Drugs Affecting The Autonomic Nervous System ............................................................................................. 43
Chapter 15: Drugs Affecting The Central Nervous System ................................................................................................... 48
Chapter 16: Drugs Affecting The Cardiovascular And Renal Systems ................................................................................ 55
Chapter 17: Drugs Affecting The Respiratory System ........................................................................................................... 61
Chapter 18: Drugs Affecting The Hematopoietic System ...................................................................................................... 65
Chapter 19: Drugs Affecting The Immune System ............................................................................................................... 69
Chapter 20: Drugs Affecting The Gastrointestinal System..................................................................................................... 72
Chapter 21: Drugs Affecting The Endocrine System ............................................................................................................. 74
Chapter 22: Drugs Affecting The Reproductive System ........................................................................................................ 77
Chapter 23: Drugs Affecting The Integumentary System ..................................................................................................... 81
Chapter 24: Drugs Used In Treating Infectious Diseases ....................................................................................................... 85
Chapter 25: Drugs Used In Treating Inflammatory Processes .............................................................................................. 90
Chapter 26: Drugs Used In Treating Eye And Ear Disorders................................................................................................. 94
Chapter 27: Anemia................................................................................................................................................................. 96
Chapter 28: Chronic Stable Angina And Low-Risk Unstable Angina .................................................................................. 99
Chapter 29: Anxiety And Depression .................................................................................................................................. 103
Chapter 30: Asthma And Chronic Obstructive Pulmonary Disease .................................................................................... 105
Chapter 31: Contraception ..................................................................................................................................................... 108
Chapter 32: Dermatologic Conditions ................................................................................................................................... 111
Chapter 33: Diabetes Mellitus ............................................................................................................................................... 114
Chapter 34: Gastroesophageal Reflux And Peptic Ulcer Disease ....................................................................................... 119
Chapter 35: Headaches .......................................................................................................................................................... 122
Chapter 36: Heart Failure ...................................................................................................................................................... 125
Chapter 37: Human Immunodeficiency Virus Disease And Acquired Immunodefiency Syndrome ................................... 128
Chapter 38: Hormone Replacement Therapy And Osteoporosis ......................................................................................... 131
Chapter 39: Hyperlipidemia .................................................................................................................................................. 134
Chapter 40: Hypertension ...................................................................................................................................................... 137
Chapter 41: Hyperthyroidism And Hypothyroidism ............................................................................................................. 140
Chapter 42: Pneumonia ......................................................................................................................................................... 142
,Chapter 43: Smoking Cessation ............................................................................................................................................ 144
Chapter 44: Sexually Transmitted Infections And Vaginitis ................................................................................................ 147
Chapter 45: Tuberculosis ....................................................................................................................................................... 150
Chapter 46: Upper Respiratory Infections: Otitis Media And Otitis Externa....................................................................... 152
Chapter 47: Urinary Tract Infections .................................................................................................................................... 154
Chapter 48: Women As Patients .......................................................................................................................................... 156
Chapter 49: Men As Patients ................................................................................................................................................. 159
Chapter 50: Pediatric Patients ............................................................................................................................................... 161
,Chapter 1: The Role Of The Nurse Practitioner As Prescriber
Multiple Choice
Identify The Choice That Best Completes The Statement Or Answers The Question.
1. Nurse Practitioner Prescriptive Authority Is Regulated By:
A. The National Council Of State Boards Of Nursing
B. The U.S. Drug Enforcement Administration
C. The State Board Of Nursing For Each State
D. The State Board Of Pharmacy
2. Physician Assistant (PA) Prescriptive Authority Is Regulated By:
A. The National Council Of State Boards Of Nursing
B. The U.S. Drug Enforcement Administration
C. The State Board Of Nursing
D. The State Board Of Medical Examiners
3. Clinical Judgment In Prescribing Includes:
A. Factoring In The Cost To The Patient Of The Medication Prescribed
B. Always Prescribing The Newest Medication Available For The Disease Process
C. Handing Out Drug Samples To Poor Patients
D. Prescribing All Generic Medications To Cut Costs
4. Criteria For Choosing An Effective Drug For A Disorder Include:
A. Asking The Patient What Drug They Think Would Work Best For Them
B. Consulting Nationally Recognized Guidelines For Disease Management
C. Prescribing Medications That Are Available As Samples Before Writing A Prescription
D. Following U.S. Drug Enforcement Administration (DEA) Guidelines
For Prescribing
5. Nurse Practitioner Practice May Thrive Under Health-Care Reform Due To:
A. The Demonstrated Ability Of Nurse Practitioners To Control Costs And Improve
Patient Outcomes
B. The Fact That Nurse Practitioners Will Be Able To Practice Independently
C. The Fact That Nurse Practitioners Will Have Full Reimbursement Under
Health-Care Reform
D. The Ability To Shift Accountability For Medicaid To The State Level
,Chapter 1: The Role Of The Nurse Practitioner As Prescriber
Answer Section
MULTIPLE CHOICE
1. ANS: C PTS: 1
2. ANS: D PTS: 1
3. ANS: A PTS: 1
4. ANS: B PTS: 1
5. ANS: A PTS: 1
Chapter 2: Review Of Basic Principles Of Pharmacology
Multiple Choice
Identify The Choice That Best Completes The Statement Or Answers The Question.
1. A Patient’s Nutritional Intake And Lab Work Reflects Hypoalbuminemia. This Is
Critical To Prescribing Because:
A. Distribution Of Drugs To Target Tissue May Be Affected
B. The Solubility Of The Drug Will Not Match The Site Of Absorption
C. There Will Be Less Free Drug Available To Generate An Effect
D. Drugs Bound To Albumin Are Readily Excreted By The Kidney
2. Drugs That Have A Significant First-Pass Effect:
A. Must Be Given By The Enteral (Oral) Route Only
B. Bypass The Hepatic Circulation
C. Are Rapidly Metabolized By The Liver And May Have Little If Any Desired Action
D. Are Converted By The Liver To More Active And Fat-Soluble Forms
3. The Route Of Excretion Of A Volatile Drug Will Likely Be:
A. The Kidneys
B. The Lungs
C. The Bile And Feces
D. The Skin
4. Medroxyprogesterone (Depo Provera) Is Prescribed IM To Create A Storage Reservoir Of
The Drug. Storage Reservoirs:
A. Assure That The Drug Will Reach Its Intended Target Tissue
B. Are The Reason For Giving Loading Doses
C. Increase The Length Of Time A Drug Is Available And Active
D. Are Most Common In Collagen Tissues
5. The NP Chooses To Give Cephalexin Every 8 Hours Based On Knowledge Of The Drug’s:
A. Propensity To Go To The Target Receptor
B. Biological Half-Life
C. Pharmacodynamics
D. Safety And Side Effects
6. Azithromycin Dosing Requires The First Day’s Dose Be Twice Those Of The Other 4
Days Of The Prescription. This Is Considered A Loading Dose. A Loading Dose:
A. Rapidly Achieves Drug Levels In The Therapeutic Range
B. Requires Four To Five Half-Lives To Attain
, C. Is Influenced By Renal Function
D. Is Directly Related To The Drug Circulating To The Target Tissues
7. The Point In Time On The Drug Concentration Curve That Indicates The First Sign Of A
Therapeutic Effect Is The:
A. Minimum Adverse Effect Level
B. Peak Of Action
C. Onset Of Action
D. Therapeutic Range
8. Phenytoin Requires A Trough Level Be Drawn. Peak And Trough Levels Are Done:
A. When The Drug Has A Wide Therapeutic Range
B. When The Drug Will Be Administered For A Short Time Only
C. When There Is A High Correlation Between The Dose And Saturation Of Receptor Sites
D. To Determine If A Drug Is In The Therapeutic Range
9. A Laboratory Result Indicates The Peak Level For A Drug Is Above The Minimum
Toxic Concentration. This Means That The:
A. Concentration Will Produce Therapeutic Effects
B. Concentration Will Produce An Adverse Response
C. Time Between Doses Must Be Shortened
D. Duration Of Action Of The Drug Is Too Long
10. Drugs That Are Receptor Agonists May Demonstrate What Property?
A. Irreversible Binding To The Drug Receptor Site
B. Up-Regulation With Chronic Use
C. Desensitization Or Down-Regulation With Continuous Use
D. Inverse Relationship Between Drug Concentration And Drug Action
11. Drugs That Are Receptor Antagonists, Such As Beta Blockers, May Cause:
A. Down-Regulation Of The Drug Receptor
B. An Exaggerated Response If Abruptly Discontinued
C. Partial Blockade Of The Effects Of Agonist Drugs
D. An Exaggerated Response To Competitive Drug Agonists
12. Factors That Affect Gastric Drug Absorption Include:
A. Liver Enzyme Activity
B. Protein-Binding Properties Of The Drug Molecule
C. Lipid Solubility Of The Drug
D. Ability To Chew And Swallow
13. Drugs Administered Via Intravenous (IV) Route:
A. Need To Be Lipid Soluble In Order To Be Easily Absorbed
B. Begin Distribution Into The Body Immediately
C. Are Easily Absorbed If They Are Nonionized
D. May Use Pinocytosis To Be Absorbed
14. When A Medication Is Added To A Regimen For A Synergistic Effect, The Combined Effect
Of The Drugs Is:
A. The Sum Of The Effects Of Each Drug Individually
B. Greater Than The Sum Of The Effects Of Each Drug Individually
C. Less Than The Effect Of Each Drug Individually
D. Not Predictable, As It Varies With Each Individual
,15. Which Of The Following Statements About Bioavailability Is True?
A. Bioavailability Issues Are Especially Important For Drugs With Narrow
Therapeutic Ranges Or Sustained Release Mechanisms.
B. All Brands Of A Drug Have The Same Bioavailability.
C. Drugs That Are Administered More Than Once A Day Have Greater
Bioavailability Than Drugs Given Once Daily.
D. Combining An Active Drug With An Inert Substance Does Not Affect Bioavailability.
16. Which Of The Following Statements About The Major Distribution Barriers (Blood-Brain Or
Fetal-Placental) Is True?
A. Water Soluble And Ionized Drugs Cross These Barriers Rapidly.
B. The Blood-Brain Barrier Slows The Entry Of Many Drugs Into And From Brain Cells.
C. The Fetal-Placental Barrier Protects The Fetus From Drugs Taken By The Mother.
D. Lipid Soluble Drugs Do Not Pass These Barriers And Are Safe For Pregnant Women.
17. Drugs Are Metabolized Mainly By The Liver Via Phase I Or Phase II Reactions. The
Purpose Of Both Of These Types Of Reactions Is To:
A. Inactivate Prodrugs Before They Can Be Activated By Target Tissues
B. Change The Drugs So They Can Cross Plasma Membranes
C. Change Drug Molecules To A Form That An Excretory Organ Can Excrete
D. Make These Drugs More Ionized And Polar To Facilitate Excretion
18. Once They Have Been Metabolized By The Liver, The Metabolites May Be:
A. More Active Than The Parent Drug
B. Less Active Than The Parent Drug
C. Totally “Deactivated” So That They Are Excreted Without Any Effect
D. All Of The Above
19. All Drugs Continue To Act In The Body Until They Are Changed Or Excreted. The
Ability Of The Body To Excrete Drugs Via The Renal System Would Be Increased By:
A. Reduced Circulation And Perfusion Of The Kidney
B. Chronic Renal Disease
C. Competition For A Transport Site By Another Drug
D. Unbinding A Nonvolatile Drug From Plasma Proteins
20. Steady State Is:
A. The Point On The Drug Concentration Curve When Absorption Exceeds Excretion
B. When The Amount Of Drug In The Body Remains Constant
C. When The Amount Of Drug In The Body Stays Below The MTC
D. All Of The Above
21. Two Different Pain Meds Are Given Together For Pain Relief. The Drug-Drug Interaction Is:
A. Synergistic
B. Antagonistic
C. Potentiative
D. Additive
22. Actions Taken To Reduce Drug-Drug Interaction Problems Include All Of The
Following EXCEPT:
A. Reducing The Dose Of One Of The Drugs
B. Scheduling Their Administration At Different Times
C. Prescribing A Third Drug To Counteract The Adverse Reaction Of The Combination
, D. Reducing The Dosage Of Both Drugs
23. Phase I Oxidative-Reductive Processes Of Drug Metabolism Require Certain
Nutritional Elements. Which Of The Following Would Reduce Or Inhibit This
Process?
A. Protein Malnutrition
B. Iron Deficiency Anemia
C. Both A And B
D. Neither A Nor B
24. The Time Required For The Amount Of Drug In The Body To Decrease By 50% Is Called:
A. Steady State
B. Half-Life
C. Phase II Metabolism
D. Reduced Bioavailability Time
25. An Agonist Activates A Receptor And Stimulates A Response. When Given Frequently
Over Time The Body May:
A. Up-Regulate The Total Number Of Receptors
B. Block The Receptor With A Partial Agonist
C. Alter The Drug’s Metabolism
D. Down-Regulate The Numbers Of That Specific Receptor
26. Drug Antagonism Is Best Defined As An Effect Of A Drug That:
A. Leads To Major Physiologic Psychological Dependence
B. Is Modified By The Concurrent Administration Of Another Drug
C. Cannot Be Metabolized Before Another Dose Is Administered
D. Leads To A Decreased Physiologic Response When Combined With Another Drug
27. Instructions To A Client Regarding Self-Administration Of Oral Enteric-Coated Tablets
Should Include Which Of The Following Statements?
A. “Avoid Any Other Oral Medicines While Taking This Drug.”
B. “If Swallowing This Tablet Is Difficult, Dissolve It In 3 Ounces Of Orange Juice.”
C. “The Tablet May Be Crushed If You Have Any Difficultly Taking It.”
D. “To Achieve Best Effect, Take The Tablet With At Least 8 Ounces Of Fluid.”
28. The Major Reason For Not Crushing A Sustained Release Capsule Is That, If Crushed, The
Coated Beads Of The Drugs Could Possibly Result In:
A. Disintegration
B. Toxicity
C. Malabsorption
D. Deterioration
29. Which Of The Following Substances Is The Most Likely To Be Absorbed In The Intestines
Rather Than In The Stomach?
A. Sodium Bicarbonate
B. Ascorbic Acid
C. Salicylic Acid
D. Glucose
30. Which Of The Following Variables Is A Factor In Drug Absorption?
A. The Smaller The Surface Area For Absorption, The More Rapidly The Drug Is Absorbed.
B. A Rich Blood Supply To The Area Of Absorption Leads To Better Absorption.
C. The Less Soluble The Drug, The More Easily It Is Absorbed.
, D. Ionized Drugs Are Easily Absorbed Across The Cell Membrane.
31. An Advantage Of Prescribing A Sublingual Medication Is That The Medication Is:
A. Absorbed Rapidly
B. Excreted Rapidly
C. Metabolized Minimally
D. Distributed Equally
32. Drugs That Use CYP 3A4 Isoenzymes For Metabolism May:
A. Induce The Metabolism Of Another Drug
B. Inhibit The Metabolism Of Another Drug
C. Both A And B
D. Neither A Nor B
33. Therapeutic Drug Levels Are Drawn When A Drug Reaches Steady State. Drugs Reach
Steady State:
A. After The Second Dose
B. After Four To Five Half-Lives
C. When The Patient Feels The Full Effect Of The Drug
D. One Hour After IV Administration
34. Up-Regulation Or Hypersensitization May Lead To:
A. Increased Response To A Drug
B. Decreased Response To A Drug
C. An Exaggerated Response If The Drug Is Withdrawn
D. Refractoriness Or Complete Lack Of Response
PHARMACOTHERAPEUTICS FOR NURSE PRACTITIONER
PRESCRIBERS 3RD EDITION
BY WOO (COVERS ALL CHAPTERS 1-50 WITH ANSWER KEY)
,TABLE OF CONTENTS
Chapter 1: The Role Of The Nurse Practitioner As Prescriber ................................................................................................. 4
Chapter 2: Review Of Basic Principles Of Pharmacology ....................................................................................................... 5
Chapter 3: Rational Drug Selection......................................................................................................................................... 10
Chapter 4: Legal And Professional Issues In Prescribing ....................................................................................................... 13
Chapter 5: Adverse Drug Reactions ........................................................................................................................................ 15
Chapter 6: Factors That Foster Positive Outcomes ................................................................................................................. 18
Chapter 7: Cultural And Ethnic Influences In Pharmacotherapeutics..................................................................................... 21
Chapter 8: Pharmacogenomics ................................................................................................................................................ 23
Chapter 9: Nutritional Supplements And Nutraceuticals ........................................................................................................ 26
Chapter 10: Herbal And Complementary Medicine ............................................................................................................... 31
Chapter 11: Information Technology And Pharmacotherapeutics ......................................................................................... 34
Chapter 12: Pharmacoeconomics............................................................................................................................................. 37
Chapter 13: Over-The-Counter Medications ........................................................................................................................... 40
Chapter 14: Drugs Affecting The Autonomic Nervous System ............................................................................................. 43
Chapter 15: Drugs Affecting The Central Nervous System ................................................................................................... 48
Chapter 16: Drugs Affecting The Cardiovascular And Renal Systems ................................................................................ 55
Chapter 17: Drugs Affecting The Respiratory System ........................................................................................................... 61
Chapter 18: Drugs Affecting The Hematopoietic System ...................................................................................................... 65
Chapter 19: Drugs Affecting The Immune System ............................................................................................................... 69
Chapter 20: Drugs Affecting The Gastrointestinal System..................................................................................................... 72
Chapter 21: Drugs Affecting The Endocrine System ............................................................................................................. 74
Chapter 22: Drugs Affecting The Reproductive System ........................................................................................................ 77
Chapter 23: Drugs Affecting The Integumentary System ..................................................................................................... 81
Chapter 24: Drugs Used In Treating Infectious Diseases ....................................................................................................... 85
Chapter 25: Drugs Used In Treating Inflammatory Processes .............................................................................................. 90
Chapter 26: Drugs Used In Treating Eye And Ear Disorders................................................................................................. 94
Chapter 27: Anemia................................................................................................................................................................. 96
Chapter 28: Chronic Stable Angina And Low-Risk Unstable Angina .................................................................................. 99
Chapter 29: Anxiety And Depression .................................................................................................................................. 103
Chapter 30: Asthma And Chronic Obstructive Pulmonary Disease .................................................................................... 105
Chapter 31: Contraception ..................................................................................................................................................... 108
Chapter 32: Dermatologic Conditions ................................................................................................................................... 111
Chapter 33: Diabetes Mellitus ............................................................................................................................................... 114
Chapter 34: Gastroesophageal Reflux And Peptic Ulcer Disease ....................................................................................... 119
Chapter 35: Headaches .......................................................................................................................................................... 122
Chapter 36: Heart Failure ...................................................................................................................................................... 125
Chapter 37: Human Immunodeficiency Virus Disease And Acquired Immunodefiency Syndrome ................................... 128
Chapter 38: Hormone Replacement Therapy And Osteoporosis ......................................................................................... 131
Chapter 39: Hyperlipidemia .................................................................................................................................................. 134
Chapter 40: Hypertension ...................................................................................................................................................... 137
Chapter 41: Hyperthyroidism And Hypothyroidism ............................................................................................................. 140
Chapter 42: Pneumonia ......................................................................................................................................................... 142
,Chapter 43: Smoking Cessation ............................................................................................................................................ 144
Chapter 44: Sexually Transmitted Infections And Vaginitis ................................................................................................ 147
Chapter 45: Tuberculosis ....................................................................................................................................................... 150
Chapter 46: Upper Respiratory Infections: Otitis Media And Otitis Externa....................................................................... 152
Chapter 47: Urinary Tract Infections .................................................................................................................................... 154
Chapter 48: Women As Patients .......................................................................................................................................... 156
Chapter 49: Men As Patients ................................................................................................................................................. 159
Chapter 50: Pediatric Patients ............................................................................................................................................... 161
,Chapter 1: The Role Of The Nurse Practitioner As Prescriber
Multiple Choice
Identify The Choice That Best Completes The Statement Or Answers The Question.
1. Nurse Practitioner Prescriptive Authority Is Regulated By:
A. The National Council Of State Boards Of Nursing
B. The U.S. Drug Enforcement Administration
C. The State Board Of Nursing For Each State
D. The State Board Of Pharmacy
2. Physician Assistant (PA) Prescriptive Authority Is Regulated By:
A. The National Council Of State Boards Of Nursing
B. The U.S. Drug Enforcement Administration
C. The State Board Of Nursing
D. The State Board Of Medical Examiners
3. Clinical Judgment In Prescribing Includes:
A. Factoring In The Cost To The Patient Of The Medication Prescribed
B. Always Prescribing The Newest Medication Available For The Disease Process
C. Handing Out Drug Samples To Poor Patients
D. Prescribing All Generic Medications To Cut Costs
4. Criteria For Choosing An Effective Drug For A Disorder Include:
A. Asking The Patient What Drug They Think Would Work Best For Them
B. Consulting Nationally Recognized Guidelines For Disease Management
C. Prescribing Medications That Are Available As Samples Before Writing A Prescription
D. Following U.S. Drug Enforcement Administration (DEA) Guidelines
For Prescribing
5. Nurse Practitioner Practice May Thrive Under Health-Care Reform Due To:
A. The Demonstrated Ability Of Nurse Practitioners To Control Costs And Improve
Patient Outcomes
B. The Fact That Nurse Practitioners Will Be Able To Practice Independently
C. The Fact That Nurse Practitioners Will Have Full Reimbursement Under
Health-Care Reform
D. The Ability To Shift Accountability For Medicaid To The State Level
,Chapter 1: The Role Of The Nurse Practitioner As Prescriber
Answer Section
MULTIPLE CHOICE
1. ANS: C PTS: 1
2. ANS: D PTS: 1
3. ANS: A PTS: 1
4. ANS: B PTS: 1
5. ANS: A PTS: 1
Chapter 2: Review Of Basic Principles Of Pharmacology
Multiple Choice
Identify The Choice That Best Completes The Statement Or Answers The Question.
1. A Patient’s Nutritional Intake And Lab Work Reflects Hypoalbuminemia. This Is
Critical To Prescribing Because:
A. Distribution Of Drugs To Target Tissue May Be Affected
B. The Solubility Of The Drug Will Not Match The Site Of Absorption
C. There Will Be Less Free Drug Available To Generate An Effect
D. Drugs Bound To Albumin Are Readily Excreted By The Kidney
2. Drugs That Have A Significant First-Pass Effect:
A. Must Be Given By The Enteral (Oral) Route Only
B. Bypass The Hepatic Circulation
C. Are Rapidly Metabolized By The Liver And May Have Little If Any Desired Action
D. Are Converted By The Liver To More Active And Fat-Soluble Forms
3. The Route Of Excretion Of A Volatile Drug Will Likely Be:
A. The Kidneys
B. The Lungs
C. The Bile And Feces
D. The Skin
4. Medroxyprogesterone (Depo Provera) Is Prescribed IM To Create A Storage Reservoir Of
The Drug. Storage Reservoirs:
A. Assure That The Drug Will Reach Its Intended Target Tissue
B. Are The Reason For Giving Loading Doses
C. Increase The Length Of Time A Drug Is Available And Active
D. Are Most Common In Collagen Tissues
5. The NP Chooses To Give Cephalexin Every 8 Hours Based On Knowledge Of The Drug’s:
A. Propensity To Go To The Target Receptor
B. Biological Half-Life
C. Pharmacodynamics
D. Safety And Side Effects
6. Azithromycin Dosing Requires The First Day’s Dose Be Twice Those Of The Other 4
Days Of The Prescription. This Is Considered A Loading Dose. A Loading Dose:
A. Rapidly Achieves Drug Levels In The Therapeutic Range
B. Requires Four To Five Half-Lives To Attain
, C. Is Influenced By Renal Function
D. Is Directly Related To The Drug Circulating To The Target Tissues
7. The Point In Time On The Drug Concentration Curve That Indicates The First Sign Of A
Therapeutic Effect Is The:
A. Minimum Adverse Effect Level
B. Peak Of Action
C. Onset Of Action
D. Therapeutic Range
8. Phenytoin Requires A Trough Level Be Drawn. Peak And Trough Levels Are Done:
A. When The Drug Has A Wide Therapeutic Range
B. When The Drug Will Be Administered For A Short Time Only
C. When There Is A High Correlation Between The Dose And Saturation Of Receptor Sites
D. To Determine If A Drug Is In The Therapeutic Range
9. A Laboratory Result Indicates The Peak Level For A Drug Is Above The Minimum
Toxic Concentration. This Means That The:
A. Concentration Will Produce Therapeutic Effects
B. Concentration Will Produce An Adverse Response
C. Time Between Doses Must Be Shortened
D. Duration Of Action Of The Drug Is Too Long
10. Drugs That Are Receptor Agonists May Demonstrate What Property?
A. Irreversible Binding To The Drug Receptor Site
B. Up-Regulation With Chronic Use
C. Desensitization Or Down-Regulation With Continuous Use
D. Inverse Relationship Between Drug Concentration And Drug Action
11. Drugs That Are Receptor Antagonists, Such As Beta Blockers, May Cause:
A. Down-Regulation Of The Drug Receptor
B. An Exaggerated Response If Abruptly Discontinued
C. Partial Blockade Of The Effects Of Agonist Drugs
D. An Exaggerated Response To Competitive Drug Agonists
12. Factors That Affect Gastric Drug Absorption Include:
A. Liver Enzyme Activity
B. Protein-Binding Properties Of The Drug Molecule
C. Lipid Solubility Of The Drug
D. Ability To Chew And Swallow
13. Drugs Administered Via Intravenous (IV) Route:
A. Need To Be Lipid Soluble In Order To Be Easily Absorbed
B. Begin Distribution Into The Body Immediately
C. Are Easily Absorbed If They Are Nonionized
D. May Use Pinocytosis To Be Absorbed
14. When A Medication Is Added To A Regimen For A Synergistic Effect, The Combined Effect
Of The Drugs Is:
A. The Sum Of The Effects Of Each Drug Individually
B. Greater Than The Sum Of The Effects Of Each Drug Individually
C. Less Than The Effect Of Each Drug Individually
D. Not Predictable, As It Varies With Each Individual
,15. Which Of The Following Statements About Bioavailability Is True?
A. Bioavailability Issues Are Especially Important For Drugs With Narrow
Therapeutic Ranges Or Sustained Release Mechanisms.
B. All Brands Of A Drug Have The Same Bioavailability.
C. Drugs That Are Administered More Than Once A Day Have Greater
Bioavailability Than Drugs Given Once Daily.
D. Combining An Active Drug With An Inert Substance Does Not Affect Bioavailability.
16. Which Of The Following Statements About The Major Distribution Barriers (Blood-Brain Or
Fetal-Placental) Is True?
A. Water Soluble And Ionized Drugs Cross These Barriers Rapidly.
B. The Blood-Brain Barrier Slows The Entry Of Many Drugs Into And From Brain Cells.
C. The Fetal-Placental Barrier Protects The Fetus From Drugs Taken By The Mother.
D. Lipid Soluble Drugs Do Not Pass These Barriers And Are Safe For Pregnant Women.
17. Drugs Are Metabolized Mainly By The Liver Via Phase I Or Phase II Reactions. The
Purpose Of Both Of These Types Of Reactions Is To:
A. Inactivate Prodrugs Before They Can Be Activated By Target Tissues
B. Change The Drugs So They Can Cross Plasma Membranes
C. Change Drug Molecules To A Form That An Excretory Organ Can Excrete
D. Make These Drugs More Ionized And Polar To Facilitate Excretion
18. Once They Have Been Metabolized By The Liver, The Metabolites May Be:
A. More Active Than The Parent Drug
B. Less Active Than The Parent Drug
C. Totally “Deactivated” So That They Are Excreted Without Any Effect
D. All Of The Above
19. All Drugs Continue To Act In The Body Until They Are Changed Or Excreted. The
Ability Of The Body To Excrete Drugs Via The Renal System Would Be Increased By:
A. Reduced Circulation And Perfusion Of The Kidney
B. Chronic Renal Disease
C. Competition For A Transport Site By Another Drug
D. Unbinding A Nonvolatile Drug From Plasma Proteins
20. Steady State Is:
A. The Point On The Drug Concentration Curve When Absorption Exceeds Excretion
B. When The Amount Of Drug In The Body Remains Constant
C. When The Amount Of Drug In The Body Stays Below The MTC
D. All Of The Above
21. Two Different Pain Meds Are Given Together For Pain Relief. The Drug-Drug Interaction Is:
A. Synergistic
B. Antagonistic
C. Potentiative
D. Additive
22. Actions Taken To Reduce Drug-Drug Interaction Problems Include All Of The
Following EXCEPT:
A. Reducing The Dose Of One Of The Drugs
B. Scheduling Their Administration At Different Times
C. Prescribing A Third Drug To Counteract The Adverse Reaction Of The Combination
, D. Reducing The Dosage Of Both Drugs
23. Phase I Oxidative-Reductive Processes Of Drug Metabolism Require Certain
Nutritional Elements. Which Of The Following Would Reduce Or Inhibit This
Process?
A. Protein Malnutrition
B. Iron Deficiency Anemia
C. Both A And B
D. Neither A Nor B
24. The Time Required For The Amount Of Drug In The Body To Decrease By 50% Is Called:
A. Steady State
B. Half-Life
C. Phase II Metabolism
D. Reduced Bioavailability Time
25. An Agonist Activates A Receptor And Stimulates A Response. When Given Frequently
Over Time The Body May:
A. Up-Regulate The Total Number Of Receptors
B. Block The Receptor With A Partial Agonist
C. Alter The Drug’s Metabolism
D. Down-Regulate The Numbers Of That Specific Receptor
26. Drug Antagonism Is Best Defined As An Effect Of A Drug That:
A. Leads To Major Physiologic Psychological Dependence
B. Is Modified By The Concurrent Administration Of Another Drug
C. Cannot Be Metabolized Before Another Dose Is Administered
D. Leads To A Decreased Physiologic Response When Combined With Another Drug
27. Instructions To A Client Regarding Self-Administration Of Oral Enteric-Coated Tablets
Should Include Which Of The Following Statements?
A. “Avoid Any Other Oral Medicines While Taking This Drug.”
B. “If Swallowing This Tablet Is Difficult, Dissolve It In 3 Ounces Of Orange Juice.”
C. “The Tablet May Be Crushed If You Have Any Difficultly Taking It.”
D. “To Achieve Best Effect, Take The Tablet With At Least 8 Ounces Of Fluid.”
28. The Major Reason For Not Crushing A Sustained Release Capsule Is That, If Crushed, The
Coated Beads Of The Drugs Could Possibly Result In:
A. Disintegration
B. Toxicity
C. Malabsorption
D. Deterioration
29. Which Of The Following Substances Is The Most Likely To Be Absorbed In The Intestines
Rather Than In The Stomach?
A. Sodium Bicarbonate
B. Ascorbic Acid
C. Salicylic Acid
D. Glucose
30. Which Of The Following Variables Is A Factor In Drug Absorption?
A. The Smaller The Surface Area For Absorption, The More Rapidly The Drug Is Absorbed.
B. A Rich Blood Supply To The Area Of Absorption Leads To Better Absorption.
C. The Less Soluble The Drug, The More Easily It Is Absorbed.
, D. Ionized Drugs Are Easily Absorbed Across The Cell Membrane.
31. An Advantage Of Prescribing A Sublingual Medication Is That The Medication Is:
A. Absorbed Rapidly
B. Excreted Rapidly
C. Metabolized Minimally
D. Distributed Equally
32. Drugs That Use CYP 3A4 Isoenzymes For Metabolism May:
A. Induce The Metabolism Of Another Drug
B. Inhibit The Metabolism Of Another Drug
C. Both A And B
D. Neither A Nor B
33. Therapeutic Drug Levels Are Drawn When A Drug Reaches Steady State. Drugs Reach
Steady State:
A. After The Second Dose
B. After Four To Five Half-Lives
C. When The Patient Feels The Full Effect Of The Drug
D. One Hour After IV Administration
34. Up-Regulation Or Hypersensitization May Lead To:
A. Increased Response To A Drug
B. Decreased Response To A Drug
C. An Exaggerated Response If The Drug Is Withdrawn
D. Refractoriness Or Complete Lack Of Response
